Abstract:IL-33 regulates the function of ILC2s through ST2. However, the role of IL-33, especially exogenous IL-33, on ILC2s in tumors is controversial depending on the cytokines they secrete. Here we report that exogenous, but not endogenous, IL-33 significantly inhibits the progression of a variety of mouse solid tumors, including melanoma, colorectal cancer, lung adenoma, and breast cancer. By inoculating tumor cells in Il1rl1−/- and NSG mice, we found that the tumor-suppressive effect of IL-33 on tumors was dependent on the expression of ST2 receptors and the presence of lymphocytes. Regarding tumor-infiltrating immune cells, exogenous IL-33 significantly increases the proportions of ST2+ Tregs (1.10 ± 0.20% vs. 1.74 ± 0.36%), eosinophils (6.00 ± 1.33% vs. 22.73 ± 6.51%), Granzyme B+ CD8+ T cells (4.32 ± 2.77% vs. 11.53 ± 6.81%), and bulk ILC2s (0.08 ± 0.04% vs. 5.31 ± 1.33%) and IA/IE+ ILC2s (0.02 ± 0.01% vs. 3.67 ± 1.03%). In draining lymph nodes, IL-33 also significantly increases the proportions of ILC2s (0.03 ± 0.02‰ vs. 6.37 ± 1.71‰) and IA/IE+ ILC2s (0.003 ± 0.003‰ vs. 4.38 ± 1.21‰). Importantly, single-cell transcriptomic analysis on tumor-infiltrating ILC2s highlights the expression of genes related with antigen processing and presentation including H2-K1, H2-Q7, B2m, Hspa1a, Hspa1b, Creb1, Hspa4, Tap1 and Tap2. We testified this finding by DQ-OVA experiment and found that IL-33 could promote ILC2s to up-take and process exogenous antigens (17.78 ± 0.75 fold vs. 22.02 ± 0.75 fold). The antigen presentation function of ILC2s was further established by mixed lymphocyte culture where BALB/c ILC2s potently stimulated C57BL/6 CD8+ T cell proliferation, which was further augmented by IL-33 treatment. Taken together, our data demonstrate an anti-tumor function of therapeutic IL-33 that elevates the number and antigen presentation function of ILC2s. Citation Format: Jie Liu, Zhenchu Feng, Hongyan Wei, Chang Li, Xiaoshi Li, Wenlong Chen, Yixi Ke, Minjun Wang, Lantian Liu, Cunni Zheng, Quan Liu. Therapeutic IL-33 enhances the antigen presentation function of ILC2s to exert anti-tumor immune activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2700.

E3 Ligase VHL Promotes Group 2 Innate Lymphoid Cell Maturation and Function Via Glycolysis Inhibition and Induction of Interleukin-33 Receptor.

The E3 Ligase VHL Controls Lung Inflammation by Regulating Epithelium-ILC2 Cross-talk

The E3 Ligase VHL Promotes Follicular Helper T Cell Differentiation Via Glycolytic-Epigenetic Control.

E3 Ubiquitin Ligase Vhl Regulates Hypoxia-Inducible Factor-1 Alpha To Maintain Regulatory T Cell Stability And Suppressive Capacity

The E3 Ligase VHL Controls Alveolar Macrophage Function Via Metabolic-Epigenetic Regulation

Blocking the HIF-1α/glycolysis axis inhibits allergic airway inflammation by reducing ILC2 metabolism and function

Differential Role of Id2 in the Group 3 Innate Lymphoid Cells for the Development of Different Gut Associated Lymphoid Tissues

Interleukin-33 and Interferon-γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation

Functions of Group 2 Innate Lymphoid Cells in Tumor Microenvironment

ILC2s Improve Glucose Metabolism Through the Control of Saturated Fatty Acid Absorption Within Visceral Fat

Heterogeneity of Group 2 Innate Lymphoid Cells Defines Their Pleiotropic Roles in Cancer, Obesity, and Cardiovascular Diseases

Hypoxia induces adrenomedullin from lung epithelia, stimulating ILC2 inflammation and immunity

VHL loss enhances antitumor immunity by activating the anti-viral DNA-sensing pathway

The ETS1 Transcription Factor is Required for the Development and Cytokine-Induced Expansion of ILC2.

Group-2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2-Neutrophil-Induced Immunosuppression.

IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia

Group 2 innate lymphoid cells boost CD8+ T-cell activation in anti-tumor immune responses

Abstract 2700: Therapeutic IL-33 enhances the antigen presentation function of ILC2s to exert anti-tumor immune activity

The group 2 innate lymphoid cell (ILC2) regulatory network and its underlying mechanisms

Group‐2 Innate Lymphoid Cells Promote Hepatocellular Carcinoma Progression via CXCL2‐Neutrophil Induced Immunosuppression

Maturation and specialization of group 2 innate lymphoid cells through the lung-gut axis